跳至主要内容
临床试验/ISRCTN62866759
ISRCTN62866759已完成3 期

A phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma

niversity of Heidelberg (Germany)0 个研究点目标入组 110 人开始时间: 2005年2月16日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Biopsy proven completely resected (R0 or R1) pancreatic adenocarcinoma of the pancreatic head or uncinate process (American Joint Committee on Cancer [AJCC] Stage I-III)
  • 2. Protocol treatment must begin within 12 weeks of surgery
  • 3. Men and women over eighteen years of age

排除标准

  • Does not comply with above inclusion criteria

研究者

发起方
niversity of Heidelberg (Germany)

相似试验

进行中(未招募)
不适用
A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
EUCTR2010-019071-29-GBBioVex, Inc.580
进行中(未招募)
3 期
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyEstrogen Receptor NegativeHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast Carcinoma
NCT02445391ECOG-ACRIN Cancer Research Group415
尚未招募
Unknown
A study to evaluate cisplatin induced hearing loss among patients of head and neck cancers receiving chemoradiation treatment
CTRI/2024/08/072465Sri Venkateshwara Institute of medical sciences
进行中(未招募)
不适用
A Phase II study evaluating the role of the combination of cisplatin and cyclophosphamide administered metronomically in patients with advanced breast cancer triple negative (Estrogen and progesterone receptors negative and c-erb B2 non overexpressed).Advanced, triple receptor negative breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-020835-38-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
2 期
A phase II study of cisplatin with TS-1 for patients with cancer of primary unknow
JPRN-C000000271Department of Medical Oncology, Kinki University School of Medicine45